$MCRB
Seres Therapeutics, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023039439 Filed on August 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q4
Revenue $310.0K $126.5M $975.0K
YoY Change -91.0% 10300.74% -86.5%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $20.00M $28.05M $22.40M
YoY Change 8.79% 37.94% 9.26%
% of Gross Profit
Research & Development $28.25M $46.79M $46.22M
YoY Change -34.47% 6.5% 25.76%
% of Gross Profit
Depreciation & Amortization $1.684M $1.527M $1.627M
YoY Change -3.61% -9.38% 4.83%
% of Gross Profit
Operating Expenses $47.72M $76.95M $69.28M
YoY Change -23.71% 19.22% 22.29%
Operating Profit -$47.41M $49.52M
YoY Change -19.78% -178.21%
Interest Expense -$1.400M -$1.461M -$466.0K
YoY Change 62.41% 32.1% 84.19%
% of Operating Profit -2.95%
Other Income/Expense, Net -$441.0K -$1.511M -$23.00K
YoY Change -50.73% 7.16% -92.72%
Pretax Income -$47.90M $46.55M -$68.80M
YoY Change -20.17% -171.91% 37.59%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$47.85M $46.55M -$68.80M
YoY Change -20.25% -171.91% 37.59%
Net Earnings / Revenue -15436.77% 36.81% -7056.0%
Basic Earnings Per Share -$0.37 $0.36
Diluted Earnings Per Share -$0.37 $0.36 -$0.55
COMMON SHARES
Basic Shares Outstanding 128.2M 127.9M 124.6M
Diluted Shares Outstanding 128.3M 129.8M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $169.9M $229.5M $181.3M
YoY Change -27.08% 17.22% -37.62%
Cash & Equivalents $169.9M $229.5M $163.0M
Short-Term Investments $0.00 $0.00 $18.31M
Other Short-Term Assets $9.100M $8.819M $13.42M
YoY Change -37.28% -36.02% 3.88%
Inventory $18.53M $5.340M $0.00
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $214.4M $251.2M $194.8M
YoY Change -13.38% 19.88% -35.85%
LONG-TERM ASSETS
Property, Plant & Equipment $23.57M $134.3M $22.99M
YoY Change 20.95% 588.06% 28.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change -100.0%
Other Assets $12.05M $20.84M $10.47M
YoY Change 4.42% 119.16% 101.68%
Total Long-Term Assets $153.3M $155.1M $154.0M
YoY Change 138.22% 143.88% 200.64%
TOTAL ASSETS
Total Short-Term Assets $214.4M $251.2M $194.8M
Total Long-Term Assets $153.3M $155.1M $154.0M
Total Assets $367.7M $406.4M $348.8M
YoY Change 17.9% 48.75% -1.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.958M $12.92M $17.44M
YoY Change -14.27% -7.65% 26.97%
Accrued Expenses $19.80M $17.16M $18.31M
YoY Change 9.31% 10.26% 15.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $456.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $79.23M $77.90M $85.60M
YoY Change -3.17% -12.51% 4.06%
LONG-TERM LIABILITIES
Long-Term Debt $101.1M $100.7M $50.59M
YoY Change 98.79% 98.97% 105.3%
Other Long-Term Liabilities $1.579M $205.1M $1.442M
YoY Change 64.31% 21653.23% -87.46%
Total Long-Term Liabilities $1.579M $305.9M $1.442M
YoY Change 64.31% 32336.37% -87.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $79.23M $77.90M $85.60M
Total Long-Term Liabilities $1.579M $305.9M $1.442M
Total Liabilities $382.8M $383.8M $338.0M
YoY Change 56.71% 53.42% 51.33%
SHAREHOLDERS EQUITY
Retained Earnings -$937.0M -$889.1M -$864.5M
YoY Change 17.75% 20.85% 40.72%
Common Stock $921.9M $911.7M $875.3M
YoY Change 6.77% 20.12% 17.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$15.12M $22.61M $10.78M
YoY Change
Total Liabilities & Shareholders Equity $367.7M $406.4M $348.8M
YoY Change 17.9% 48.75% -1.71%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q4
OPERATING ACTIVITIES
Net Income -$47.85M $46.55M -$68.80M
YoY Change -20.25% -171.91% 37.59%
Depreciation, Depletion And Amortization $1.684M $1.527M $1.627M
YoY Change -3.61% -9.38% 4.83%
Cash From Operating Activities -$59.30M $65.98M -$52.89M
YoY Change -0.47% -232.24% 1.99%
INVESTING ACTIVITIES
Capital Expenditures $1.800M $1.233M $3.461M
YoY Change -244.35% -157.0% -319.33%
Acquisitions
YoY Change
Other Investing Activities $0.00 $11.75M $9.387M
YoY Change -100.0% -54.03% -36.42%
Cash From Investing Activities -$1.800M $10.52M $5.926M
YoY Change -104.49% -55.05% -55.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.500M 58.18M 4.597M
YoY Change -98.47% 44651.54% -689.36%
NET CHANGE
Cash From Operating Activities -59.30M 65.98M -52.89M
Cash From Investing Activities -1.800M 10.52M 5.926M
Cash From Financing Activities 1.500M 58.18M 4.597M
Net Change In Cash -59.60M 134.7M -42.37M
YoY Change -175.85% -610.76% 7.38%
FREE CASH FLOW
Cash From Operating Activities -$59.30M $65.98M -$52.89M
Capital Expenditures $1.800M $1.233M $3.461M
Free Cash Flow -$61.10M $64.75M -$56.35M
YoY Change 4.74% -235.65% 12.07%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001609809
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseAndServiceMember
CY2022Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseAndServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseAndServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseAndServiceMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37465
dei Entity Registrant Name
EntityRegistrantName
Seres Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4326290
dei Entity Address Address Line1
EntityAddressAddressLine1
200 Sidney Street - 4th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
945-9626
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Trading Symbol
TradingSymbol
MCRB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
128204614
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
229520000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
163030000
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
0
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
18311000
CY2023Q2 mcrb Collaboration Receivable Related Party
CollaborationReceivableRelatedParty
7559000
CY2022Q4 mcrb Collaboration Receivable Related Party
CollaborationReceivableRelatedParty
0
CY2023Q2 us-gaap Inventory Net
InventoryNet
5340000
CY2022Q4 us-gaap Inventory Net
InventoryNet
0
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8819000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13423000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
251238000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
194764000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24026000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22985000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
110283000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
110984000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8185000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8185000
CY2023Q2 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2022Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11254000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10465000
CY2023Q2 us-gaap Assets
Assets
406387000
CY2022Q4 us-gaap Assets
Assets
348784000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
12922000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
17440000
CY2023Q2 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
55878000
CY2022Q4 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
59840000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5470000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3601000
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
0
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
456000
CY2023Q2 us-gaap Deferred Income
DeferredIncome
2817000
CY2022Q4 us-gaap Deferred Income
DeferredIncome
0
CY2023Q2 mcrb Contract With Customer Liability Current Related Party
ContractWithCustomerLiabilityCurrentRelatedParty
811000
CY2022Q4 mcrb Contract With Customer Liability Current Related Party
ContractWithCustomerLiabilityCurrentRelatedParty
4259000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
77898000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
85596000
CY2023Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
100742000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
50591000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
106706000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
107942000
CY2023Q2 mcrb Contract With Customer Liability Noncurrent Related Party
ContractWithCustomerLiabilityNoncurrentRelatedParty
94927000
CY2022Q4 mcrb Contract With Customer Liability Noncurrent Related Party
ContractWithCustomerLiabilityNoncurrentRelatedParty
92430000
CY2023Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1968000
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1532000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1442000
CY2023Q2 us-gaap Liabilities
Liabilities
383773000
CY2022Q4 us-gaap Liabilities
Liabilities
338001000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
128037679
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
128037679
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125222273
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
125222273
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
128000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
125000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
911620000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
875181000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-889133000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-864511000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
22614000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10783000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
406387000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
348784000
CY2023Q2 mcrb Collaboration Revenue From Related Party
CollaborationRevenueFromRelatedParty
126473000
CY2022Q2 mcrb Collaboration Revenue From Related Party
CollaborationRevenueFromRelatedParty
1216000
mcrb Collaboration Revenue From Related Party
CollaborationRevenueFromRelatedParty
125951000
mcrb Collaboration Revenue From Related Party
CollaborationRevenueFromRelatedParty
2709000
CY2023Q2 us-gaap Revenues
Revenues
126473000
CY2022Q2 us-gaap Revenues
Revenues
1216000
us-gaap Revenues
Revenues
125951000
us-gaap Revenues
Revenues
2709000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46792000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43935000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
90761000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
83584000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28051000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20335000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
50521000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
38906000
CY2023Q2 mcrb Profit Loss From Research Agreements Related Party
ProfitLossFromResearchAgreementsRelatedParty
2106000
CY2022Q2 mcrb Profit Loss From Research Agreements Related Party
ProfitLossFromResearchAgreementsRelatedParty
271000
mcrb Profit Loss From Research Agreements Related Party
ProfitLossFromResearchAgreementsRelatedParty
5713000
mcrb Profit Loss From Research Agreements Related Party
ProfitLossFromResearchAgreementsRelatedParty
-705000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
76949000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
64541000
us-gaap Operating Expenses
OperatingExpenses
146995000
us-gaap Operating Expenses
OperatingExpenses
121785000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
49524000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-63325000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21044000
us-gaap Operating Income Loss
OperatingIncomeLoss
-119076000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1726000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
395000
us-gaap Investment Income Interest
InvestmentIncomeInterest
2758000
us-gaap Investment Income Interest
InvestmentIncomeInterest
779000
CY2023Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
3187000
CY2022Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
1501000
us-gaap Interest Expense Debt
InterestExpenseDebt
5135000
us-gaap Interest Expense Debt
InterestExpenseDebt
2413000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1511000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-304000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1201000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-649000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2972000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1410000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3578000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2283000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
46552000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-64735000
us-gaap Net Income Loss
NetIncomeLoss
-24622000
us-gaap Net Income Loss
NetIncomeLoss
-121359000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.36
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.7
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.36
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.7
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
127713486
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92255416
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126793342
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92224382
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
129844931
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92255416
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
126793342
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92224382
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-41000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
10000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-196000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-41000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
11000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-196000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
46549000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64776000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24611000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-121555000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
131507000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
257000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
892000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5079000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-155000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-56624000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
80956000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
130000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6748000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-41000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-64735000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
23058000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
10783000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
188000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1229000
CY2023Q1 mcrb Stock Issued During Period Value At Market Equity Offerings
StockIssuedDuringPeriodValueAtMarketEquityOfferings
4239000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6850000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
14000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-71174000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-47871000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
168000
CY2023Q2 mcrb Stock Issued During Period Value At Market Equity Offerings
StockIssuedDuringPeriodValueAtMarketEquityOfferings
7491000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2785000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13492000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
-3000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
46552000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
22614000
us-gaap Net Income Loss
NetIncomeLoss
-24622000
us-gaap Net Income Loss
NetIncomeLoss
-121359000
us-gaap Share Based Compensation
ShareBasedCompensation
20342000
us-gaap Share Based Compensation
ShareBasedCompensation
11827000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2927000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3255000
mcrb Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
4247000
mcrb Non Cash Operating Lease Cost
NonCashOperatingLeaseCost
2305000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
236000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-547000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
337000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
328000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1625000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-132000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
mcrb Profit Loss From Research Agreement Related Party
ProfitLossFromResearchAgreementRelatedParty
-5713000
mcrb Profit Loss From Research Agreement Related Party
ProfitLossFromResearchAgreementRelatedParty
705000
mcrb Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets
3579000
mcrb Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets
-10145000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
7559000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
0
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5340000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0
mcrb Increase Decrease In Defered Income Related Party
IncreaseDecreaseInDeferedIncomeRelatedParty
2817000
mcrb Increase Decrease In Contract With Customer Liability Related Party
IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty
-951000
mcrb Increase Decrease In Contract With Customer Liability Related Party
IncreaseDecreaseInContractWithCustomerLiabilityRelatedParty
-2709000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3092000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
709000
mcrb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-577000
mcrb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2130000
mcrb Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities
-9678000
mcrb Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities
1735000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10600000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-116342000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5301000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5113000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
4426000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
36138000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
22983000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
77622000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13256000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
36371000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
356000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
387000
mcrb Proceeds From Issuance Of Common Stock From At The Market Equity Offering
ProceedsFromIssuanceOfCommonStockFromAtTheMarketEquityOffering
11730000
mcrb Proceeds From Issuance Of Common Stock From At The Market Equity Offering
ProceedsFromIssuanceOfCommonStockFromAtTheMarketEquityOffering
0
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1229000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
892000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
103378000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
27606000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
52860000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1907000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
63833000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26978000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
66489000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-52993000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
0
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
171215000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
188002000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
237705000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
135009000
us-gaap Interest Paid Net
InterestPaidNet
2869000
us-gaap Interest Paid Net
InterestPaidNet
1836000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
943000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
597000
mcrb Prepaid Rent Reclassified To Right Of Use Assets
PrepaidRentReclassifiedToRightOfUseAssets
2336000
mcrb Prepaid Rent Reclassified To Right Of Use Assets
PrepaidRentReclassifiedToRightOfUseAssets
4962000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1210000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4370000
mcrb Non Financial Liabilities For Warrants Recognised
NonFinancialLiabilitiesForWarrantsRecognised
2100000
mcrb Non Financial Liabilities For Warrants Recognised
NonFinancialLiabilitiesForWarrantsRecognised
0
mcrb Warrants Issued Related To Term Loan And Recorded As Debt Discount
WarrantsIssuedRelatedToTermLoanAndRecordedAsDebtDiscount
2785000
mcrb Warrants Issued Related To Term Loan And Recorded As Debt Discount
WarrantsIssuedRelatedToTermLoanAndRecordedAsDebtDiscount
0
mcrb Accrued Expenses And Other Current And Long Term Liabilities Related Party Amounts
AccruedExpensesAndOtherCurrentAndLongTermLiabilitiesRelatedPartyAmounts
-3398000
mcrb Accrued Expenses And Other Current And Long Term Liabilities Related Party Amounts
AccruedExpensesAndOtherCurrentAndLongTermLiabilitiesRelatedPartyAmounts
-1379000
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
mcrb Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2010-10
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-889133000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
229520000
us-gaap Net Income Loss
NetIncomeLoss
-24622000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10600000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. In the unaudited condensed consolidated financial statements, the Company uses estimates and assumptions related to revenue recognition and the accrual of research and development expenses. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates.</span></p>
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8185000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8185000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
229520000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
163030000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8185000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
8185000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
237705000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
171215000
CY2023Q2 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2022Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2023Q2 mcrb Derivative Liability Expected Term
DerivativeLiabilityExpectedTerm
P1Y8M12D
CY2023Q2 mcrb Derivative Liability Expected Term
DerivativeLiabilityExpectedTerm
P1Y6M
CY2022Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2022Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0
CY2023Q2 mcrb Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2023Q2 mcrb Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2023Q2 mcrb Fair Value Assets Level1 To Level3 Transfers Amount
FairValueAssetsLevel1ToLevel3TransfersAmount
0
CY2023Q2 mcrb Fair Value Assets Level3 To Level1 Transfers Amount
FairValueAssetsLevel3ToLevel1TransfersAmount
0
CY2023Q2 mcrb Fair Value Assets Level2 To Level3 Transfers Amount
FairValueAssetsLevel2ToLevel3TransfersAmount
0
CY2023Q2 mcrb Fair Value Assets Level3 To Level2 Transfers Amount
FairValueAssetsLevel3ToLevel2TransfersAmount
0
CY2022Q2 mcrb Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2022Q2 mcrb Fair Value Assets Level1 To Level3 Transfers Amount
FairValueAssetsLevel1ToLevel3TransfersAmount
0
CY2022Q2 mcrb Fair Value Assets Level3 To Level1 Transfers Amount
FairValueAssetsLevel3ToLevel1TransfersAmount
0
CY2022Q2 mcrb Fair Value Assets Level2 To Level3 Transfers Amount
FairValueAssetsLevel2ToLevel3TransfersAmount
0
CY2022Q2 mcrb Fair Value Assets Level3 To Level2 Transfers Amount
FairValueAssetsLevel3ToLevel2TransfersAmount
0
CY2022Q2 mcrb Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
18321000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
13000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
18311000
mcrb Cash Equivalents Original Maturity Maximum Period
CashEquivalentsOriginalMaturityMaximumPeriod
P90D
CY2022 mcrb Cash Equivalents Original Maturity Maximum Period
CashEquivalentsOriginalMaturityMaximumPeriod
P90D
CY2023Q2 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2022Q4 us-gaap Restricted Investments Noncurrent
RestrictedInvestmentsNoncurrent
1401000
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
547000
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
4750000
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
43000
CY2023Q2 us-gaap Inventory Net
InventoryNet
5340000
CY2022Q4 us-gaap Inventory Net
InventoryNet
0
CY2023Q2 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
11181000
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
26794000
CY2023Q2 us-gaap Inventory Write Down
InventoryWriteDown
0
us-gaap Inventory Write Down
InventoryWriteDown
0
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
71993000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
68025000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
47967000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
45040000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24026000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22985000
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1527000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2927000
CY2022Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1685000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3255000
mcrb Disposal Of Fully Depreciated Assets Cost Basis
DisposalOfFullyDepreciatedAssetsCostBasis
9000
CY2023Q2 mcrb Accrued Clinical And Development Costs Current
AccruedClinicalAndDevelopmentCostsCurrent
2157000
CY2022Q4 mcrb Accrued Clinical And Development Costs Current
AccruedClinicalAndDevelopmentCostsCurrent
6717000
CY2023Q2 mcrb Manufacturing And Quality Costs
ManufacturingAndQualityCosts
2707000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11688000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14709000
CY2023Q2 mcrb Transaction Price Allocated Under Collaborative Arrangement
TransactionPriceAllocatedUnderCollaborativeArrangement
31372000
CY2022Q4 mcrb Transaction Price Allocated Under Collaborative Arrangement
TransactionPriceAllocatedUnderCollaborativeArrangement
34770000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7954000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3644000
CY2023Q2 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
55878000
CY2022Q4 mcrb Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
59840000
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
Certain leases include one or more options to renew, exercisable at the Company’s sole discretion, with renewal terms that can extend the lease from approximately one year to five years.
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2022Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P10Y
CY2022Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
110283000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
110984000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5470000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3601000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
106706000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
107942000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
112176000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
111543000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
70735000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
112176000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y5M19D
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
5543000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1948000
us-gaap Operating Lease Cost
OperatingLeaseCost
10953000
us-gaap Operating Lease Cost
OperatingLeaseCost
3620000
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
372000
CY2022Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
354000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
740000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
709000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
2180000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
1271000
us-gaap Variable Lease Cost
VariableLeaseCost
3943000
us-gaap Variable Lease Cost
VariableLeaseCost
2302000
CY2023Q2 us-gaap Lease Cost
LeaseCost
8095000
CY2022Q2 us-gaap Lease Cost
LeaseCost
3573000
us-gaap Lease Cost
LeaseCost
15636000
us-gaap Lease Cost
LeaseCost
6631000
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
3875000
us-gaap Operating Lease Payments
OperatingLeasePayments
7289000
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
1332000
us-gaap Operating Lease Payments
OperatingLeasePayments
3445000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
8600000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
19437000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
21555000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
22155000
CY2023Q2 mcrb Lessee Operating Lease Liability To Be Paid After Year Three
LesseeOperatingLeaseLiabilityToBePaidAfterYearThree
111164000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
182911000
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.13
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.10
CY2023Q2 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
50446000
CY2023Q2 us-gaap Debt Instrument Convertible Threshold Trading Days
DebtInstrumentConvertibleThresholdTradingDays
30
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
24750000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
33000000
CY2023Q2 mcrb Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
52250000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
110000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14940034
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.03
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y3M
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11608000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2430545
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.49
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
105592
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.37
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
509388
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.39
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
16755599
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.43
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6828000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
9772084
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.94
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M20D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5882000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.54
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.56
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.5
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.6
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13492000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6748000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20342000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11827000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
46552000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-64735000
us-gaap Net Income Loss
NetIncomeLoss
-24622000
us-gaap Net Income Loss
NetIncomeLoss
-121359000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
46552000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-64735000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24622000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-121359000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
127713486
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92255416
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126793342
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92224382
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.36
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.7
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
46552000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-64735000
us-gaap Net Income Loss
NetIncomeLoss
-24622000
us-gaap Net Income Loss
NetIncomeLoss
-121359000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
46552000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-64735000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-24622000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-121359000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
127713486
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92255416
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126793342
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
92224382
CY2023Q2 mcrb Incremental Common Shares Attributable To Dilutive Effect Of Stock Options To Purchase Common Stock
IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsToPurchaseCommonStock
1597058
CY2023Q2 mcrb Incremental Common Shares Attributable To Dilutive Effect Of Unvested Restricted Stock Units
IncrementalCommonSharesAttributableToDilutiveEffectOfUnvestedRestrictedStockUnits
519338
CY2023Q2 mcrb Incremental Common Shares Attributable To Dilutive Effect Of Share Issuable Under Employee Stock Purchase Plan
IncrementalCommonSharesAttributableToDilutiveEffectOfShareIssuableUnderEmployeeStockPurchasePlan
15049
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
129844931
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92255416
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
126793342
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
92224382
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.36
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.7
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
CY2016Q1 mcrb Collaborative Arrangement Upfront License Fee Received
CollaborativeArrangementUpfrontLicenseFeeReceived
120000000
CY2023Q2 mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
1473000
CY2022Q2 mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
1216000
mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
951000
mcrb Contract With Customer Liability Revenue Recognized With Related Party
ContractWithCustomerLiabilityRevenueRecognizedWithRelatedParty
2709000
CY2023Q2 mcrb Share Of Related Party Net Loss
ShareOfRelatedPartyNetLoss
-2141000
CY2022Q2 mcrb Share Of Related Party Net Loss
ShareOfRelatedPartyNetLoss
0
mcrb Share Of Related Party Net Loss
ShareOfRelatedPartyNetLoss
-2141000
mcrb Share Of Related Party Net Loss
ShareOfRelatedPartyNetLoss
0
CY2023Q2 mcrb Profit On Transfer Of Related Party Inventory
ProfitOnTransferOfRelatedPartyInventory
1273000
CY2022Q2 mcrb Profit On Transfer Of Related Party Inventory
ProfitOnTransferOfRelatedPartyInventory
0
mcrb Profit On Transfer Of Related Party Inventory
ProfitOnTransferOfRelatedPartyInventory
1273000
mcrb Profit On Transfer Of Related Party Inventory
ProfitOnTransferOfRelatedPartyInventory
0
CY2023Q2 mcrb Collaboration Profit Loss Related To Pre Launch Activities
CollaborationProfitLossRelatedToPreLaunchActivities
-1238000
CY2022Q2 mcrb Collaboration Profit Loss Related To Pre Launch Activities
CollaborationProfitLossRelatedToPreLaunchActivities
-271000
mcrb Collaboration Profit Loss Related To Pre Launch Activities
CollaborationProfitLossRelatedToPreLaunchActivities
-4845000
mcrb Collaboration Profit Loss Related To Pre Launch Activities
CollaborationProfitLossRelatedToPreLaunchActivities
705000
CY2023Q2 mcrb Profit Loss From Research Agreement Related Party
ProfitLossFromResearchAgreementRelatedParty
-2106000
CY2022Q2 mcrb Profit Loss From Research Agreement Related Party
ProfitLossFromResearchAgreementRelatedParty
-271000
mcrb Profit Loss From Research Agreement Related Party
ProfitLossFromResearchAgreementRelatedParty
-5713000
mcrb Profit Loss From Research Agreement Related Party
ProfitLossFromResearchAgreementRelatedParty
705000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q2 us-gaap Deferred Income
DeferredIncome
2817000
CY2022Q4 us-gaap Deferred Income
DeferredIncome
0
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-23-039439-index-headers.html Edgar Link pending
0000950170-23-039439-index.html Edgar Link pending
0000950170-23-039439.txt Edgar Link pending
0000950170-23-039439-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
mcrb-20230630.htm Edgar Link pending
mcrb-20230630.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mcrb-20230630_cal.xml Edgar Link unprocessable
mcrb-20230630_def.xml Edgar Link unprocessable
mcrb-ex31_1.htm Edgar Link pending
mcrb-ex31_2.htm Edgar Link pending
mcrb-ex32_1.htm Edgar Link pending
mcrb-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
mcrb-20230630_pre.xml Edgar Link unprocessable
mcrb-20230630_htm.xml Edgar Link completed
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
mcrb-20230630_lab.xml Edgar Link unprocessable